Lower numbers of podocytes per glomerulus were observed in UNX+vehicle 38 compared to sham-op and this was prevented in UNX+R-568 but not in UNX+calcitriol. In 39 parallel, albuminuria was higher in untreated UNX compared to sham-op and the increase was 40 prevented in UNX+R-568. Interstitial fibrosis was more prevalent in vehicle treated UNX 41 compared to sham-op group and this was prevented in UNX treated with R-568 and less 42 effectively with calcitriol. In all UNX groups the weight of residual kidney was significantly 43 higher compared to all sham-op. No difference was observed in serum ionized calcium and 44 systolic blood pressure between the groups. 45
Introduction

50
Chronic kidney disease (CKD) progresses over time even if the primary insult is no 51 longer operative (6). Secondary hyperparathyroidism (sHPT) is a common feature of chronic 52 kidney disease. Elevated parathyroid hormone (PTH) concentrations have been demonstrated 53 to contribute to heart fibrosis in uremia (1). PTH is also thought to play a role in progression 54 of kidney damage (24). Both active vitamin D metabolites and calcimimetics are indicated for 55 the treatment of sHPT. Experimental data suggest that lowering PTH with either active 56 vitamin D or calcimimetics may slow progression of advanced kidney damage (20) . 57
In a previous study in a model of more advanced kidney damage we showed that the 58 calcimimetic R-568 and calcitriol prevented podocyte loss and ultrastructure, as well as 59 In vitro data indicate a direct, pro-survival effects of calcimimetics on podocytes and 65 protection from direct toxicity (18) . Some data suggest similar podocyte protection by active 66 vitamin D (10). 67
For this study we chose a model of less severe kidney dysfunction, without rise of 68 blood pressure and presumably without secondary hyperparathyroidism (3). The goal of this 69 study was to evaluate whether a calcimimetic or active vitamin D prevent podocyte damage in 70 vivo in the absence of elevated PTH levels. 71 72
Materials and Methods
73
All animals were handled according to written approval from the local authority for 74 animal experiments (Regierungspraesidium Karlsruhe). The investigation conforms to the 75 Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 76
Health (NIH Publication No. 85-23, revised 1996) . 12-weeks old male ApoE -/-mice were 77 randomized to undergo sham operation or unilateral nephrectomy (UNX) and received a 78 standard rodent diet containing 19.3% protein, 39.1% carbohydrates, and 3.3% fat 1.00% 79 calcium, 0.70% phosphate, and 0.68% potassium (Ssniff, Soest, Germany) and tap water ad 80 libitum. The mice after UNX were randomized to receive the calcimimetic R-568 81 (4 µg/kg/day), calcitriol (0.03 µg/kg/day) or vehicle administered daily intraperitoneally. The 82 dose of R-568, lower than used in rats (21), was determined in a pilot experiment as well 83 tolerated by the mice. The sham-operated mice received the vehicle. The treatment was 84 continued for 12 weeks; body weight was measured weekly. 85
Blood pressure was measured by tail-cuff plethysmography in conscious mice at week 86 12 post UNX as described previously (23). 87 24-hour urine samples were collected in metabolic cages at week 12 of treatment. 88
Blood samples were collected from the abdominal aorta at the time of sacrifice. Serum and 89 urine parameters (sodium, potassium, calcium, phosphate, creatinine, total and HDL 90 cholesterol, triglycerides) and blood cells were analyzed using standard laboratory methods. 91 Parathormone (PTH) was measured in plasma by a mouse-specific ELISA kit according to 92 manufacturer's recommendations (Immutopics Int., San Clemente, CA, USA). 93
Urinary albumin was measured by a mouse-specific ELISA kit according to 94 manufacturer's recommendations (Bethyl Laboratories, Montgomery, TX, USA). 95
After the 12-week treatment period tissue samples were collected by pressure-96 controlled perfusion. The abdominal aorta was catheterized under anesthesia (100 mg/kg 97 ketamine hydrochloride and 3.0 mg/kg xylazine). Blood samples were taken; the vasculature 98 was flushed with 0.9% NaCl solution and collected for molecular investigations or fixed with 99 glutaraldehyde and collected for morphologic investigations. 100
Morphological and Stereological Evaluation 101
All investigations were performed in a blinded manner; i.e., the observer was unaware 102 of the study protocol. 103
Glomerular sclerosis index (GSI) was assessed on PAS-stained paraffin sections 104 according to the semiquantitative scoring system (score 0 -4) proposed by El Nahas et al.
(4). 105
With use of light microscopy and ×400 magnification, the glomerular score of each animal 106 was derived as the arithmetic mean of 100 glomeruli. The tubular and interstitial damage 107 scores were evaluated separately on the same PAS-stained sections, with evaluation of every 108 field of view at ×400 magnification. 109
The indices of tubulointerstitial (TII) and vascular damage (VI) were also assessed at a 110 magnification of ×100 using similar scoring systems (22). The number of glomeruli per 111 kidney and mean glomerular volume were determined using the point counting method as 112 previously described (22). Capillaries and the number and volume of glomerular cells were 113 analyzed in semithin sections at ×1000 magnification using the point-counting method as 114 previously described (22 Immunohistochemistry 139 Immunohistochemical analysis was performed on paraffin sections using antibodies 140 against VDR (Santa Cruz Biotechnology), CaSR (Affinity BioReagents), desmin (Dako, 141 Copenhagen, Denmark), synaptopodin, ZO-1, Neph-1, p-Bad (Santa Cruz Biotechnology), 142
angiotensin II type 1 and type 2 receptors, and ACE (Abcam, Cambridge, UK) and the 143 streptavidin-biotin technique with alkaline phosphatase as the labeling enzyme. All antibodies 144 had been tested for specificity in mice, and the optimal concentration for staining was 145 evaluated by testing different dilutions in a pilot study. Negative controls were performed by 146 omitting the primary antibody. The staining was analyzed by an investigator blinded with 147 respect to the animal groups. For desmin, p-Bad, angiotensin II type 1 and type 2 receptors, 148
and ACE the average number of stained cells per glomerulus was calculated in all visible 149 glomeruli. For synaptopodin, ZO-1, and Neph-1 stained area was measured in individual 150 glomeruli using Vario Vision Pro 3.2 software (Soft Imaging System) and an average was 151 calculated for each case. 152
Quantitative stereology of the heart 153 All investigations were performed by an observer unaware of the animal group. The 154 length density (Lv) of capillaries, i.e. the length of capillaries per unit tissue volume, was 155 measured in eight systematically subsampled areas per section and intercapillary distance was 156 calculated according to a formula by Henquell and Honig as previously described (23). 157
Statistical analysis 158
Data are given as mean ± SD or median and range as appropriate. For western blots, 159 the vehicle-treated sham-op group served as reference and the mean value of individual 160 measurements was set as 100%. One-way analysis of variance (ANOVA) was used followed 161 by Duncan's multiple range test for differences between groups. 162 163
Results
164
Animal data 165
There was no difference in final body weight between the groups (tab. 1). The left 166 kidney weight (absolute and relative to body weight) was higher in all three UNX groups 167 without any effect of the treatment. At the end of the study systolic blood pressure was not 168 different between the groups. Albuminuria at the end of the study was significantly higher in 169 UNX compared with sham-op mice. Compared with untreated UNX albumin excretion was 170 significantly lower in UNX treated with R-568 but not in those treated with calcitriol (table  171   1) . 172
Serum ionized calcium and phosphate concentrations were not different between the 173 groups. After UNX no elevation of serum PTH concentration was observed and the serum 174 PTH concentration was unaffected by any treatment. 175
Kidney morphology 176
The glomerulosclerosis and vascular indices were significantly higher in all UNX 177 compared with sham-op without any effect of the treatments (table 3) . 178
The tubulointerstitial index and interstitial fibrosis were significantly higher in all 179 UNX compared to sham-op ( The foot podocyte process effacement was more marked in UNX+V and 202
UNX+calcitriol compared with sham-op and was prevented in UNX treated with R-568 (table  203 5, fig. 1 ). 204
CaSR and VDR 205
The extranuclear staining for CaSR and VDR both in the tubulointerstital 206 compartment and in glomeruli was not significantly different between the groups. There was 207 no difference in CaSR and VDR expression by Western blotting as well ( fig. 2) . 208
Components of the renin-angiotensin system 209
The expression of the angiotensin converting enzyme (ACE) was significantly higher 210 in UNX compared with sham-op mice ( fig. 3) The expression of the angiotensin converting enzyme 2 (ACE2) was significantly 217 higher in all UNX compared with sham-op mice without any significant effect of the 218 treatments ( fig. 3) . 219
The expression of the angiotensin II type 1 receptor (AT1R) was significantly higher 220 in UNX compared with sham-op mice ( fig. 3) . Compared with untreated UNX it was 221 significantly lower in UNX treated with R-568 but not in UNX treated with calcitriol. In 222 glomeruli AT1R stained extranuclear. In UNX mice there was significantly more cells stained 223
for AT1R compared to sham-op (fig. 4) . The number of cells positive for AT1R was 224 significantly lower in UNX treated with R-568 compared to untreated UNX. There was no 225 difference in the number of cells positive for AT1R between untreated UNX and UNX treated 226 with calcitriol. 227
The expression of the angiotensin II type 2 receptor (AT2R) was significantly higher 228 in UNX compared with sham-op mice ( fig. 3) . Compared with untreated UNX it was 229 significantly lower in UNX treated both with R-568 and calcitriol, but in both these groups it 230 was still higher compared with sham-op mice. In glomeruli AT2R stained the extranuclear 231
and there was no difference in the number of cells stained for AT2R between sham-op and 232 UNX mice (fig. 4) . 233
The expression of renin was significantly higher in UNX compared with sham-op 234 mice ( fig. 3 ). Both R-568 and calcitriol prevented the increase in renin expression in UNX 235 mice. 236
The expression of the renin receptor was not different between sham-op and untreated 237 UNX mice, but it was significantly higher in UNX treated with calcitriol ( fig. 3) . 238
Podocyte proteins 239
Significantly more podocytes per glomerulus were stained positive for desmin in the 240 cytoplasm in UNX mice treated with vehicle compared to sham-op (tab. 6). This increase was 241 ameliorated in UNX mice treated with either R-568 or calcitriol, but the number of desmin-242 stained cells was still higher compared to sham-op ( fig. 4) . 243
Staining for synaptopodin, ZO-1, and Neph-1 in the membrane was significantly less 244 in glomeruli of vehicle-treated UNX mice compared to sham-op (tab. 6). Neither R-568 nor 245 calcitriol influenced staining for synaptopodin. The area stained for ZO-1 and Neph-1 was 246 significantly greater in UNX treated with R-568 or calcitriol compared to those treated with 247 vehicle (fig. 4) . 248
Apoptosis marker 249
Significantly more cells per glomerulus stained positively (perinuclear) for 250 phosphorylated Bad (p-Bad) in untreated UNX mice compare with sham-op and this was 251 prevented in UNX treated with R-568. 252
Heart capillary density 253
The capillary length density was significantly (ANOVA p<0.001) lower, and the mean 254 intercapillary distance was significantly higher, in untreated UNX mice (2210±222 mm/mm mice stained for phosphorylated Bad -a protein involved in apoptosis (27), which was 278 prevented in UNX mice treated with R-568. This suggests that R-568 ameliorated podocyte 279 apoptosis in line with previous in vitro observations (18) . 280
Angiotensin II is well known to perpetuate kidney and specifically podocyte damage 281 (7). VDR activators have been shown to ameliorate kidney damage by inhibiting the renin-282 angiotensin system (29) and VDR activation directly suppresses renin gene transcription (28). 283
Calcimimetics also lower renin release (11). In line with those observations we have shown 284 that both calcitriol and R-568 lowered increased renin expression in the remnant kidney. The 285 calcimimetic, however, also decreased the expression of ACE and AT1 receptor specifically 286 in the glomeruli, which were unaffected by calcitriol. The suppression of several components 287 of the renin-angiotensin system by R-568 may explain the protective effect of the 288 calcimimetic. This was opposed by a specific renin inhibition by calcitriol and failure to 289 prevent podocyte damage in this study. Angiotensin-converting enzyme 2 (ACE2) degrades 290 angiotensin II to angiotensin-(1-7), is expressed in podocytes, and may prevent podocyte 291 damage (13). In this model, however, it seems not to play a role in podocyte protection as its 292 expression was not significantly affected by both treatments. 293
In this model podocyte loss has been observed without an increase in systemic blood 294 pressure. In agreement with previous studies in ApoE -/-mice blood pressure did not increase 295 after UNX (23). Similarly, the protection of podocyte damage by the calcimimetic was shown 296 without lowering blood pressure. Although calcimimetics were shown to decrease blood 297 pressure (14, 15), this effect had been observed in animals with increased blood pressure and 298 more extensive kidney damage. The indirect method of blood pressure measurement is a 299 limitation of this study. 300
The serum ionized calcium concentration was not different between the groups when 301 measured 24h post-dosing as the decrease of serum calcium after the administration of R-568 302 is known to be transient (5). At the dose used, calcitriol did not cause hypercalcemia in 303 agreement with previous experiments (2). 304
Reduction of nephron number leads to podocyte injury and this contributes to the 305 development of glomerulosclerosis (12). 306
In line with the decreased podocyte number in UNX mice we observed increased 307 urinary albumin excretion. The reduction of albuminuria by R-568 treatment in UNX mice 308 confirms that the observed preservation of podocyte number and ultrastructure in this group 309 provides functional benefits. Again, UNX mice treated with calcitriol failed to maintain 310 podocyte number or to significantly reduce albuminuria. This is in contrast to previous 311 observations that VDR activation leads to lower albuminuria (9, 20) but those observation 312
were made in models of more advanced kidney damage with greater increase in albuminuria. 313
Furthermore, amelioration of albuminuria in those studies was observed together with a 314 decrease in PTH concentrations. Lowering PTH by parathyreoidectomy is sufficient to reduce 315 albuminuria in the renal ablation model (17). Our results indicate that the reduction of 316 albuminuria by a calcimimetic is, at least in part, independent of the effects on PTH. 317 It was previously shown by Yoshida et al. (26) that at an early stage of 318 glomerulosclerosis a positive correlation is found between glomerulosclerosis index and 319 glomerular volume. Podocytes are thought to play a pivotal role in the development of 320 glomerular scarring (12). We observed only a slight increase and no effect of treatments on 321 glomerulusclerosis in UNX mice. There were however differences in glomerular volume -in 322 parallel with the lower podocyte number, glomerular volume was higher in UNX mice treated 323 with vehicle or calcitriol and glomerular volume was lower in UNX treated with R-568 324 accompanying the preservation of podocyte number. 325
In contrast to observations in subtotally nephrectomized rats (20) we observed no 326 difference in expression of VDR and CaSR between UNX and sham-op mice, most probably 327 due to the lower severity of kidney damage in the current model. 328
The quantitative assessment of protein expression in whole cortex lysates repressents 329 both glomerular and tubular localization and it is a limitation of this study. Semiquantitative 330 data from immunohistochemical staining provides more insight into glomerular expression of 331 investigated proteins. 332
ApoE -/-mice develop accelerated atherosclerosis already after uninephrectomy (23). 333 R-568 ameliorated capillary rarefaction in the heart, indirectly suggesting that it might 334 ameliorate atherosclerotic lesions, which have been demonstrated previously in rats (8). 335
In conclusion, in a model of subtle reduction of kidney function the calcimimetic R-336 568 prevented podocyte loss, glomerular enlargement as well as albuminuria. These effects 337
were observed without changes in parathormone concentration and systolic blood pressure 338 suggesting a direct effect on podocytes. Whether such effects can be extrapolated to humans 339 remains unknown. It offers, however, a potential new treatment option for delaying 340 progressive kidney failure. 341 
